Evidence map›Paper›PMID 33750426›Full record

ArticleGenome medicine2021

Genetic disruption of serine biosynthesis is a key driver of macular telangiectasia type 2 aetiology and progression.

Roberto Bonelli, Brendan R E Ansell, Luca Lotta, Thomas Scerri, Traci E Clemons, Irene Leung, MacTel Consortium, Tunde Peto, Alan C Bird, Ferenc B Sallo and 2 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Genetic Background of Macular Telangiectasia Type 2.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Macular Telangiectasia Type 2: A Comprehensive Review.Clinical ophthalmology (Auckland, N.Z.) · 2022
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Roberto BonelliDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, 3052, Australia.
Brendan R E AnsellDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, 3052, Australia.
Luca LottaMRC Epidemiology Unit, University of Cambridge, Cambridge, CB2 0SL, UK.
Thomas ScerriDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, 3052, Australia.
Traci E ClemonsThe EMMES Corporation, Rockville, MD, 20850, USA.
Irene LeungDepartment of Research and Development, Moorfields Eye Hospital NHS Foundation Trust, London, EC1V 2PD, UK.
MacTel Consortium
Tunde PetoDepartment of Ophthalmology, Queen's University, Belfast, BT7 1NN, UK.
Alan C BirdInherited Eye Disease, Moorfields Eye Hospital NHS Foundation Trust, London, EC1V 2PD, UK.
Ferenc B SalloDepartment of Ophthalmology, Hôpital Ophtalmique Jules-Gonin, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland.
Claudia LangenbergMRC Epidemiology Unit, University of Cambridge, Cambridge, CB2 0SL, UK.
Melanie BahloDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria, 3052, Australia. bahlo@wehi.edu.au.ORCID 0000-0001-5132-0774
The University of Melbourne · AUMoorfields Eye Hospital NHS Foundation Trust · GBUniversity of Cambridge · GBEmmes (United States) · USHôpital Ophtalmique Jules-Gonin · CHQueen's University Belfast · GB

Funding

Medical Research Council MC_UU_00006/1
6 · The paper itself

Abstract

backgroundMacular telangiectasia type 2 (MacTel) is a rare, heritable and largely untreatable retinal disorder, often comorbid with diabetes. Genetic risk loci subtend retinal vascular calibre and glycine/serine/threonine metabolism genes. Serine deficiency may contribute to MacTel via neurotoxic deoxysphingolipid production; however, an independent vascular contribution is also suspected. Here, we use statistical genetics to dissect the causal mechanisms underpinning this complex disease.

methodsWe integrated genetic markers for MacTel, vascular and metabolic traits, and applied Mendelian randomisation and conditional and interaction genome-wide association analyses to discover the causal contributors to both disease and spatial retinal imaging sub-phenotypes.

resultsGenetically induced serine deficiency is the primary causal metabolic driver of disease occurrence and progression, with a lesser, but significant, causal contribution of type 2 diabetes genetic risk. Conversely, glycine, threonine and retinal vascular traits are unlikely to be causal for MacTel. Conditional regression analysis identified three novel disease loci independent of endogenous serine biosynthetic capacity. By aggregating spatial retinal phenotypes into endophenotypes, we demonstrate that SNPs constituting independent risk loci act via related endophenotypes.

conclusionsFollow-up studies after GWAS integrating publicly available data with deep phenotyping are still rare. Here, we describe such analysis, where we integrated retinal imaging data with MacTel and other traits genomics data to identify biochemical mechanisms likely causing this disorder. Our findings will aid in early diagnosis and accurate prognosis of MacTel and improve prospects for effective therapeutic intervention. Our integrative genetics approach also serves as a useful template for post-GWAS analyses in other disorders.

Indexed as

Disease ProgressionGenetic Predisposition to DiseaseBiosynthetic PathwaysDiabetes Mellitus, Type 2EndophenotypesGenetic LociGenome-Wide Association StudyHumansMetabolomePolymorphism, Single NucleotideRetinal TelangiectasisRetinal VesselsSerineSerineGWASMendelian randomisationMetabolomicsRetinal diseaseSerine

Identifiers

PMID33750426
PMCPMC7945323
OpenAlexW3138012501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.